CytoGenix Announces Results of Annual Shareholder Meeting.HOUSTON Houston, city (1990 pop. 1,630,553), seat of Harris co., SE Tex., a deepwater port on the Houston Ship Channel; inc. 1837. Economy The fourth largest city in the nation and the largest in the entire South and Southwest, Houston is a port of entry; -- CytoGenix, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYGX) announced today the results of proposals considered at its annual meeting of stockholders held July July: see month. 14, in Houston. CytoGenix shareholders re-elected two directors, for a three-year term, to serve on the company's board, including Dr. Cy Stein Stein , William Howard 1911-1980. American biochemist. He shared a 1972 Nobel Prize for pioneering studies of ribonuclease. and Mr. Frank Vazquez. Dr. Malcolm Skolnick, CytoGenix Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , commented, "We are pleased to have directors of the caliber of Cy and Frank on the board. Their qualifications, scientific and business acumen acumen Astuteness, perception, perspicacity are invaluable. With the re-election of these directors, the size of CytoGenix board remains at seven directors, four of whom are independent directors." The results of the election were as follows:
Proposal #1 Election of Directors:
For Withheld
------------------- ---------------- ----------------
Frank Vazquez 95,815,360 364,656
------------------- ---------------- ----------------
Cy A. Stein 95,831,960 348,056
------------------- ---------------- ----------------
% Voted 99.63% 0.37%
------------------- ---------------- ----------------
Proposal #2 Approval of the 2005 Employee Stock Option Plan
For Against Abstain
------------------- ---------------- ---------------- ---------------
Total shares Voted 63,543,885 4,111,802 454,150
------------------- ---------------- ---------------- ---------------
% of Vote 93.29% 6.03% 0.66%
------------------- ---------------- ---------------- ---------------
% of Outstanding 56.10% 3.63% 0.40%
------------------- ---------------- ---------------- ---------------
Proposal #3 Approval of Lopez, Blevins, Bork & Associates, LLP as
Independent Auditors
For Against Abstain
------------------- ---------------- ---------------- ---------------
Total Shares Voted 95,984,456 160,460 35,100
------------------- ---------------- ---------------- ---------------
% of Voted 99.79% 0.16% 0.03%
------------------- ---------------- ---------------- ---------------
% of Outstanding 84.74% 0.14% 0.03%
------------------- ---------------- ---------------- ---------------
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity Purity: see Pearl, The. Purity See also Modesty. almond symbol of the Virgin Mary’s innocence. [O.T.: Numbers 17: 1–11; Art: Hall, 14] crystal its transparency symbolizes pureness. DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. at fraction of the cost of traditional fermentation fermentation, process by which the living cell is able to obtain energy through the breakdown of glucose and other simple sugar molecules without requiring oxygen. Fermentation is achieved by somewhat different chemical sequences in different species of organisms. methods. CytoGenix currently has one issued U.S. patent and 41 international or U.S. pending patent applications claiming methods and materials in connection with this platform technology. SAFE HARBOR Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. : Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion